×
About 141,840 results

ALLMedicine™ Schizophrenia Center

Research & Reviews  67,129 results

Perceived major experiences of discrimination, ethnic group, and risk of psychosis in a...
https://doi.org/10.1017/S0033291721000453
Psychological Medicine; Misra S, Gelaye B et. al.

Mar 2nd, 2021 - Perceived discrimination is associated with worse mental health. Few studies have assessed whether perceived discrimination (i) is associated with the risk of psychotic disorders and (ii) contributes to an increased risk among minority ethnic grou...

Situational context influences the degree of hostile attributions made by individuals w...
https://doi.org/10.1111/bjc.12283
The British Journal of Clinical Psychology; Zajenkowska A, Rogoza R et. al.

Mar 2nd, 2021 - Previous work has demonstrated that the tendency to make hostile attributions is not a stable trait but varies across different social situations. Therefore, we sought to investigate whether hostile attributions within clinical samples are better ...

Morbidity and mortality in schizophrenia with comorbid substance use disorders.
https://doi.org/10.1111/acps.13291
Acta Psychiatrica Scandinavica; Lähteenvuo M, Batalla A et. al.

Mar 2nd, 2021 - Schizophrenia is highly comorbid with substance use disorders (SUD) but large epidemiological cohorts exploring the prevalence and prognostic significance of SUD are lacking. Here, we investigated the prevalence of SUD in patients with schizophren...

Genomic perspectives on the circadian clock hypothesis of psychiatric disorders.
https://doi.org/10.1016/bs.adgen.2020.11.005
Advances in Genetics; von Schantz M, Leocadio-Miguel MA et. al.

Mar 1st, 2021 - Circadian rhythm disturbances are frequently described in psychiatric disorders such as major depressive disorder, bipolar disorder, and schizophrenia. Growing evidence suggests a biological connection between mental health and circadian rhythmici...

see more →

Guidelines  45 results

The American Psychiatric Association Practice Guideline for the Treatment of Patients W...
https://doi.org/10.1176/appi.ajp.2020.177901
The American Journal of Psychiatry; Keepers GA, Fochtmann LJ et. al.

Sep 1st, 2020 - The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.|2020|Keepers GA,Fochtmann LJ,Anzia JM,Benjamin S,Lyness JM,|methods,methods,methods,classification,therapeutic use,diagnosis,therapy,

CAPLYTA® (lumateperone) | Now Approved | caplyta.com‎
https://www.caplyta.com/‎

Jan 13th, 2020 - Learn about a new treatment. See full safety information, PI, and boxed warning. Get information about this orally administered capsule. Press Release. Prescribing Information. MOA. Important Safety Info. Dosing & Administration.

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated r...
https://doi.org/10.1177/0269881119889296
Journal of Psychopharmacology (Oxford, England); Barnes TR, Drake R et. al.

Dec 12th, 2019 - These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, i...

Cannabidiol as a potential treatment for psychosis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843725/
Therapeutic Advances in Psychopharmacology; Davies C,et al

Nov 7th, 2019 - Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the 1950s revolutionised the treat...

U.S. FDA Approves SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia
http://www.noven.com/PR101519.php

Oct 14th, 2019 - Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced the U.S. Food and Drug Administration (FDA) has approved SECUADO® (asenapine) transdermal system, the first-and-only transdermal patch fo...

see more →

Drugs  1,629 results see all →

Clinicaltrials.gov  70,341 results

Perceived major experiences of discrimination, ethnic group, and risk of psychosis in a...
https://doi.org/10.1017/S0033291721000453
Psychological Medicine; Misra S, Gelaye B et. al.

Mar 2nd, 2021 - Perceived discrimination is associated with worse mental health. Few studies have assessed whether perceived discrimination (i) is associated with the risk of psychotic disorders and (ii) contributes to an increased risk among minority ethnic grou...

Situational context influences the degree of hostile attributions made by individuals w...
https://doi.org/10.1111/bjc.12283
The British Journal of Clinical Psychology; Zajenkowska A, Rogoza R et. al.

Mar 2nd, 2021 - Previous work has demonstrated that the tendency to make hostile attributions is not a stable trait but varies across different social situations. Therefore, we sought to investigate whether hostile attributions within clinical samples are better ...

Morbidity and mortality in schizophrenia with comorbid substance use disorders.
https://doi.org/10.1111/acps.13291
Acta Psychiatrica Scandinavica; Lähteenvuo M, Batalla A et. al.

Mar 2nd, 2021 - Schizophrenia is highly comorbid with substance use disorders (SUD) but large epidemiological cohorts exploring the prevalence and prognostic significance of SUD are lacking. Here, we investigated the prevalence of SUD in patients with schizophren...

'Landmark' Schizophrenia Drug in the Wings? 
https://www.medscape.com/viewarticle/946727

Mar 1st, 2021 - A novel therapy that combines a muscarinic receptor agonist with an anticholinergic agent is associated with a greater reduction in psychosis symptoms compared with placebo, new research shows. In a randomized phase 2 trial comprised of nearly 200...

see more →

News  2,663 results

'Landmark' Schizophrenia Drug in the Wings? 
https://www.medscape.com/viewarticle/946727

Mar 1st, 2021 - A novel therapy that combines a muscarinic receptor agonist with an anticholinergic agent is associated with a greater reduction in psychosis symptoms compared with placebo, new research shows. In a randomized phase 2 trial comprised of nearly 200...

Inflammatory Immune Findings Likely in Acute Schizophrenia, MDD, Bipolar
https://www.medscape.com/viewarticle/946603

Feb 28th, 2021 - Researchers have come a long way in understanding the link between acute inflammation and treatment-resistant depression, but more work needs to be done, according to Mark Hyman Rapaport, MD. "Inflammation has been a hot topic in the past decade, ...

Clozapine Still Underused in Refractory Schizophrenia
https://www.medscape.com/viewarticle/945771

Feb 11th, 2021 - With the exception of clozapine, the selection of an antipsychotic medication for acute treatment is driven by side effects. That's a key pearl of wisdom that Stephen R. Marder, MD, shared during a discussion of key criteria for choosing an antips...

Placenta's Role in Schizophrenia 'Bigger Than We Imagined'
https://www.medscape.com/viewarticle/945722

Feb 11th, 2021 - Schizophrenia-related genes in the placenta are predictive of the size of a baby's brain at birth and the rate of cognitive development. In a complicated pregnancy, such genes could raise the risk of developing schizophrenia later in life, new res...

Antipsychotic Prescriptions Rising Much Faster than Psychosis Rates
https://www.medscape.com/viewarticle/945257

Feb 3rd, 2021 - While the rates of antipsychotic prescription in England doubled between 2007 and 2014, the odds of having psychotic symptoms rose only slightly over the same period, according to a new study published in  Schizophrenia Research. The researchers u...

see more →

Patient Education  33 results see all →